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The detection of pathogen-derived molecules as foreign particles by adaptive immune cells triggers T and B lymphocytes to
mount protective cellular and humoralresponses, respectively. Recent immunologicaladvances elucidated that proteins and some
lipids are the principle biological molecules that induce protective T cell responses during microbial infections. Polysaccharides
are important components of microbial pathogens and many vaccines. However, research concerning the activation of the
adaptive immune system by polysaccharides gained interest only recently. Traditionally, polysaccharides were considered to
be T cell-independent antigens that did not directly activate T cells or induce protective immune responses. Here, we review
several recent advances in “carbohydrate immunobiology”. A group of bacterial polysaccharides that are known as “zwitterionic
polysaccharides (ZPSs)” were recently identiﬁed as potent immune modulators. The immunomodulatory eﬀect of ZPSs required
antigen processing and presentation by antigen presenting cells, the activation of CD4 T cells and subpopulations of CD8 T cells
andthemodulationofhostcytokineresponses.Inthisreview,wealsodiscussthepotentialuseoftheseuniqueimmunomodulatory
ZPSs in new vaccination strategies against chronic inﬂammatory conditions, autoimmunity, infectious diseases, allergies and
asthmaticconditions.
1.Introduction
The primary role ofthe immune system is to protect the host
from microbial invasions and infections. While nonspeciﬁc,
innate immune mechanisms mediate the ﬁrst stage of
transient protection against the invading pathogens, more
advanced adaptive immune mechanisms prevent microbial
invasions and infections by activating antigen-speciﬁc T and
B cells. Adaptive immune responses are superior to innate
immunity because they provide pathogen speciﬁcity and
immunological memory, which eﬀectively prevents future
reinfections of the host by the same pathogens [1].
The generation of eﬀective adaptive immune responses
to infectious agents requires the recognition of invading
microbial pathogens by T and B cells. While B cells can
recognize the native protein antigens on pathogen surfaces,
T cells do not directly recognize the surface molecules
of pathogens. T cells speciﬁcally recognize the processed
antigenic components of invading pathogens [2]. An excep-
tion to this are the superantigens, a group of powerful
antigens occurring in various bacteria and viruses that
bind outside of the normal T cell receptor (TCR) site,
reacting with multiple TCR molecules and activating T cells
nonspeciﬁcally [3, 4]. Antigen presenting cells (APCs) are a
group of specialized cells that eﬃciently process and present
both self-and nonself pathogen-derived antigens to T cells
for recognition [5–7]. Professional APCs, such as dendritic
cells (DCs), macrophages, and B cells, eﬃciently process
pathogen-derived molecules in their cellular compartments
togenerateantigenicfragmentsthatcanbeloadedintomajor2 International Journal of Microbiology
histocompatibility molecules (MHCs). MHCs then present
the antigenic fragments to T cells for recognition [5]. While
CD4+ T cells recognize antigens presented by MHC class
II (MHCII) molecules, antigens presented by MHC class
I (MHCI) are recognized by CD8+ T cells. Even though
microbial pathogens are composed of proteins, carbohy-
drates, lipids, and nucleic acids, only protein antigens are
currently believed to be processed and presented on MHC
molecules by APCs for T-cell recognition and activation
[5, 8–10]. Several studies that used TCR transgenic mouse
models show that T cells are positively selected by peptide-
MHC complexes in the thymic cortex, and the availability
of the crystal structures for TCR-peptide-MHC-complexes
[11] reinforces the theory that T cells only recognize peptide
antigens. The results of these studies further conﬁrmed the
notion that only proteinaceous antigens induce adaptive
T cell responses. However, important questions remain as
to whether nonproteinaceous antigens can activate T cells
in an MHC-restricted manner. The discovery of the CD1-
mediated presentation of glycolipids to γδT cells [12, 13]
and αβTCR+ NK T cells [14] suggests that T cells can also
recognize non-protein molecules. However, carbohydrate
antigens, which are important components of pathogenic
organisms and conjugated vaccines, were considered to
be T cell-independent antigens that are not presented on
MHC molecules and do not induce T cell activation [15].
However, recent advances in research of antigen processing
and presentation and carbohydrate immunobiology are
challenging this traditional concept.
2.BacterialZwitterionicPolysaccharides
ActivateCD4T Cells
Mostofthenaturallyoccurring polysaccharide moleculesare
composed of negatively charged (anionic) sugar molecules.
These anionic sugar molecules fail to activate T cells and do
not induce B-cell antibody isotype switching [16]. However,
Dennis Kasper’s laboratory identiﬁed a group of bacterial
polysaccharides thatcarry both positive and negative charges
in the same repeating sugar molecules and are thus called
“zwitterionic polysaccharides (ZPSs)” [17–22]. Pathogenic
strains of bacteria, such as Bacteroides fragilis (B. fragilis),
Streptococcus pneumoniae (S. pneumoniae), and Staphylococ-
cus aureus (S.a u r e u s ), produce ZPSs [22–24]. The capsular
polysaccharide antigens PSA of B. fragilis (NCTC 9343 and
638R) [22]a n dS p 1o fS. pneumoniae serotype 1 [24]a r e
the most widely studied ZPSs. The biological activities of
ZPSs from diﬀerent bacterial strains are very similar, and
therefore, in this article, we use the term ZPS to represent
all of them. ZPSs display an extended right-handed helix
structure in which two repeating sugar units per turn form
grooves with positive charges exposed on the outer surface
(Figure 1)[ 24, 25] .D u et ot h i su n i q u es t r u c t u r e ,Z P S s
possess immunomodulatory activities, unlike other polysac-
charides [26–28]. Experimental studies in rats and mice
have shown that intraperitoneal challenges with ZPSs and
the sterile cecal content (SCC) adjuvant induced pathogenic
conditions, such as intra-abdominal abscesses [26, 29].
SCC alone failed to induce abscess formation. However,
subcutaneous vaccinations using only ZPSs prior to the
intraperitoneal challengespreventedabscess inductions[30].
Intra-abdominal abscessformation,which commonlyoccurs
during secondary peritonitis and abdominal surgeries, is
a protective mechanism used by the body to limit the
spread of microbial pathogens. In the initial and subsequent
studies of ZPSs, ZPS-induced pathologies were shown to
be T-cell dependent. In those experiments, T-cell-deﬁcient
mice were unable to form abscesses after inoculations with
ZPSs [31, 32]. Further experiments with α/βTCR-knockout
mice revealed that abscess formations were dependent on
α/β TCR+ T cells [33]. The activation of CD4 T cells is
required for ZPS-mediated intra-abdominal abscess induc-
tion because mice lacking CD4 T cells failed to develop
abscesses [33]. As abscess formation was inhibited by the
transfer of T cells from animals that were immunized with
ZPS [34], these results suggest that abscess inductions and
protection in the presence of ZPS are likely mediated by
T-cell components of the adaptive immune system.
The immunomodulatory eﬀects of ZPSs require both
positive and negative charge motifs as neutralization of a
single charge motif abrogates the biological activities of
ZPSs [26]. The abscess-inducing capabilities of B. fragilis,
which carries a mutant non-ZPS molecule, are severely
attenuated [35]. On the other hand, the conversion of a non-
zwitterionic molecule into a zwitterion makes the molecule
biologically active [27, 36]. These studies suggest that unlike
most other polysaccharides, ZPSs represent a unique group
of carbohydrates that are able to activate components of the
adaptive immune system.
3.The Processing and Presentationof ZPSsfor
CD4 T-CellActivation
The activation of T cells by proteinaceous antigens requires
antigen processing and presentation on MHC molecules
followed by TCR recognition of peptide-MHC complexes
on the surfaces of APCs [5, 6]. Alternatively, mitogenic
bacterial superantigens can nonspeciﬁcally activate T cells
by crosslinking the MHCs of APCs and the Vβ subunits
of TCRs on cell surfaces independently of the intracellular
antigen processing and presentation pathway. The intra-
cellular antigen-processing pathways can be divided into
exogenous and endogenous pathways [6], though recent
discoveries of antigen crosspresentation and autophagy
mechanisms show signiﬁcant crosstalk between these two
pathways [9]. Because the antigen crosspresentation and
autophagy mechanisms have been reviewed elsewhere [9]
and the importance of these pathways in ZPS processing
and presentation is currently unknown, this article mainly
focuses on the conventional exogenous pathway. In the
exogenous pathway, extracellular antigens that are taken up
into the cell by pinocytosis orreceptor-mediated endocytosis
are targeted to endosomes, which then mature and fuse with
lysosomes. In the lysosomes, protein antigens are degraded
by lysosomal acid hydrolase enzymes into small antigenic
peptides that can be loaded onto MHCII molecules withInternational Journal of Microbiology 3
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Figure 1: Structure of ZPSs. (a) Repeating sugar molecules of Bacteroides fragilis PS A1 carrying zwitterionic charge motives.(b) ZPS Sp1 of
S. pneumoniae serotype 1.
the help of MHCII-like molecules (DM in mice and HLA-
DM in humans) (reviewed in [5]). The peptide-MHCII
complexes are then transported through tubule-vesicular
structures to the cell surface, where they are positioned for
TCR recognition by CD4 T cells [37, 38]. In the endogenous
pathway, intracellular foreign antigens and self-proteins are
processed by proteasomes. The generated peptide fragments
are then transported to the endoplasmic reticulum (ER) by
the transporter associated with antigen processing (TAP)
proteins. In the ER, the peptide fragments are mounted to
MHCI molecules [7, 9]. The peptide-MHCI complexes are
thentransported to the cell surface and recognized by CD8T
cells.
Recent studies have revealed that ZPSs are processed
by several components of the exogenous pathway that are
involved in the processing of protein antigens and are
discussed below. The recent observation that ZPS-mediated
activation of CD4 T cells requires direct contact with
MHCII-expressing APCs [24] suggests that an exogenouse
antigen processing pathway may exist for ZPSs. Further-
more, the ZPS-mediated activation of CD4 T cells requires
the internalization of the polysaccharides into APCs by
pinocytosis and endocytosis [39, 40]. Related studies have
revealed that the ZPS PSA1 from B. fragilis was degraded
into small polysaccharide units by nitric oxide (NO) in
the endosomal compartments [40]. The ZPS-containing
pinosomesorendosomesunderwent furthermaturationand
fused with lysosomes [39, 40]. Failure to detect ZPS localiza-
tion with endoplasmic reticulum markers (TLS and WKM,
unpublished data), suggests that these polysaccharides are
unlikely processed and presented by the endogenous antigen
processing and presentation pathway [40]. In the lysosomes,
ZPSs colocalize with MHCII molecules and various protein
antigens including ovalbumin [39, 40]. Similar to pro-
tein antigens, the acidiﬁcation of lysosomal compartments,
which activates lysosomal acid hydrolases that break down
complex protein antigens into smaller antigenic peptides,
is required for the ZPS-induced activation of CD4 T cells
[24, 40–42]. Interestingly, biochemical analysis revealed that
ZPSs bind to MHCII molecules [24, 40, 43], and that this
binding requires the zwitterionic charge motifs [40]. The
ZPS binding to MHCII molecules requires the catalytic
activity of DM, a chaperone molecule that facilitates peptide
editing and loading onto MHCII molecules in lysosomes. In
the absence of DM, ZPS failed to bind to MHCII molecules
[39, 40, 43]. Live cell imaging analysis demonstrated that
the ZPS-MHCII complex is transported by a retrograde
mechanism through MHCII tubular-vesicular structures
from the lysosomes to the cell surfaces of APCs [39]. As
expected, the retrograde MHCII-mediated transport of ZPSs
from lysosomes to the cell surface was inhibited in the
absence of DM molecules [39]. Thus, in the absence of DM4 International Journal of Microbiology
chaperone activity, ZPS is neither bound to MHCII nor
transportedtothecellsurfaceforpresentationtoCD4Tcells.
Takentogether,theabovestudiesshowthatbindingofZPSto
MHCIIin the lysosomesis not accidental,butisorchestrated
by highly speciﬁc events.
Contrary to the conventional antigens, bacterial super-
antigens do not require intracellular processing steps to bind
with MHCII [44]. Thus, the requirement for intracellular
processing and the MHCII-mediated retrograde transport
of ZPSs for APC presentation suggest that ZPSs do not
display a superantigen-like activity. In agreement with this
observation, ZPS-activated CD4 T cells used a broad V beta
(Vβ)TCRrepertoire,which isunlikesuperantigensthatusea
limitedVβ TCRrepertoire[45,46].Collectively,thesestudies
revealed a novel MHCII-mediated presentation pathway of
ZPSs to CD4 T cells (Figure 2).
While the ZPS processing and presentation and activa-
tion of adaptive immune system has recently been studied
extensively, relatively little information is available concern-
ing the innate components of the immune system in ZPS-
induced immune responses. A recent study by Wang et
al. shows that ZPS activates TLR-2, an innate pathogen
recognitionmolecule.ZPSinteractions with TLR-2 inﬂuence
both the induction of iNOS and the upregulation of
MHCII and costimulatory molecules associated with ZPS
processing and presentation to T cells. In the absence of
TLR-2, ZPS-induced secretion of interferon gamma (IFNγ)
by CD4 T cells and intra-abdominal abscess inductions
were signiﬁcantly reduced [47]. We observed that NF-
κB translocation to the nucleus by ZPS Sp1 is inhibited
in TLR-2 and TLR-4 knockout cells (unpublished data).
Lewis et al. recently reported that ZPS acidiﬁcation of
endosomal compartments enhances the processing of both
the polysaccharide and protein antigens and increases the
TLR-9 recognition of microbial nucleic acids [42]. Thus, the
ZPS-mediated activation of the adaptive immune system is
in turn enhanced by the proper ligation of innate pathogen
recognition molecules, such as those of the TLR pathway.
Since the focus of this article is ZPS modulation of the
adaptive immune system, the remaining sections will focus
on the adaptive immune responses.
The presentation of ZPSs by MHCII molecules raises
many interesting questions. First, do any lysosomal glycosi-
dase enzymes exist in mammalian cells that can break down
Z P S si n t os m a l lf r a g m e n t s ,w h i c hc a nt h e nb i n dt oM H C I I ?
Second, where do ZPSs bind to MHCII molecules? Recent
structural and functional studies have shown that unlike
MHCI molecules, the open-ended antigen-binding groove
of MHCII molecules may accommodate larger antigenic
peptides [48–50]. Thus, does DM facilitate the loading of
ZPSs exactly into the antigen-binding groove of MHCII?
Third, what size ZPS molecules are bound to MHCII
molecules? While biochemical studies indicate that ZPSs
of approximately 15–20kDa are associated with MHCII
molecules [24, 40], circular dichroism (CD) spectra analysis
suggest that a minimum of three repeating sugar molecules
are required for the ZPS helical structure and MHCII-
binding ability [51]. Thus, the sizes of ZPSs that bind to
MHCII are variable, and even the smallest ZPS fragment
that is bound to MHCII is much larger than the antigenic
peptides that are normally processed and bound to the
peptide binding groove of MHCII. This fact raises the
possibility that tails of the sugar molecules are outside of
the MHCII antigen binding groove and may be hanging on
the sides of the MHCII molecule. This conformation can
potentially aﬀect the canonical TCR and CD4-coreceptor
interactions with the MHCII-antigen complexes. Finally, do
any ZPS-speciﬁc receptors exist on the surface of APCs?
A n s w e r i n gt h e s eq u e s t i o n si si m p o r t a n tf o ru n d e r s t a n d i n g
ZPS processing and presentation on MHCII molecules and
also for the generation of more-eﬀective polysaccharide-
based vaccines to prevent diseases.
4.Mechanisms ofCD4 T-CellActivationby ZPS
As described above, due to their unique tertiary structures
[51], ZPSs possess immunostimulatory functions that have
previously been exclusively attributed to proteinaceous anti-
gens. In vitro, the stimulation of human and murine CD4
T cells with ZPSs induces cellular proliferation and inhibits
apoptosis [24, 41, 45, 52]. Costimulatory signals are also
necessary to raise suﬃcient T-cell responses to ZPSs because
T-cell proliferationwasinhibitedwhen CTL4AIgG/B7CD28
and CD40/CD40L contacts were inhibited [41]( F i g u r e2).
Thus, the activation of CD4 T cells by ZPS is dependent
on costimulatory factors. The presentation of fragmented
ZPSs by MHCII molecules implies that T-cell activation
is mediated by TCR recognition. However, it was unclear
how ZPS potentially bound to the TCR. Vβ chain repertoire
analyses of ZPS-stimulated T-cell populations showed that
a broad repertoire of subfamilies, including all of the Vβ
subfamilies, was used rather than speciﬁc Vβ genes [45,
46]. Therefore, the oligoclonal activation of T cells by
ZPS seemed probable. Clonotype mapping of T cells that
were stimulated in vitro with ZPSs showed oligoclonal T-
cell expansion [45]. This nonrestricted Vβ usage indicates
possible ZPS recognition by the CDR3 antigen-binding
domain of the TCR. However, structural analysis, such as X-
ray crystallography, is required to validate this hypothesis.
The precise mechanisms of proximal and distal TCR
signaling events associated with ZPS recognition are poorly
understood. We previously showed that ZPS stimulation
upregulatestheexpressionofCD69,anearly T-cellactivation
marker, on CD4 T cells [39]. After TCR stimulation, CD69
is rapidly upregulated by the Ras-MAP kinase signaling
pathway [53, 54], suggesting that this pathway may be
involved in ZPS-mediated T-cell activation. However, more
studies are required to determine if ZPS recognition results
in the activation of key proximal TCR signaling molecules,
such as Lck, Zap70, Lat, and SLP76 [55]. Moreover, anal-
ysis of ZPS-speciﬁc T-cell clones is required to increase
our understanding of the mechanisms of T-cell activation.
Stingele et al. fused in vitro activated rat T cells and
mouse thymoma cell line BW5147.G.1.4 to generate ZPS-
speciﬁc T-cell clones [46]. These T-cell clones showed
enhanced responses to ZPS stimulation and prevented the
intra-abdominal abscess formation in experimental models.International Journal of Microbiology 5
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However, signiﬁcant crossreactivity between ZPS subtypes,
but not with non-ZPS molecules, was observed among
these T-cell clones. The attempts to generate mouse ZPS-
speciﬁc T-cell clones in vitro have not met with success.
The diﬃculties in generating speciﬁc T-cell clones could be
due to the complex immunomodulatory activities of ZPS,
such as the induction of T-cell anergy and the generation of
IL-10-producing T cells (discussed below), which suppress
the IL-2 production required for expansion of T-cell clones
[46, 56]. As an alternative approach, clonotype mapping of
abscess-inducing CD4 T cells from mouse models shows
the existence of ZPS-speciﬁc clones [45]. It is therefore
important to know that ablation of ZPS-induced immune
suppression, such as IL-10 production and anergy, can
expand the above identiﬁed ZPS-speciﬁc CD4 T-cell clones
ex vivo.
5.ZPS InducesRegulatoryCD8T CellsUpon
TCRCrosslinking
Because most ZPS studies have been primarily focused
on CD4 T-cell interactions, the eﬀects of ZPSs on the
stimulation of CD8 T cells have only very recently been
studied. We showed that ZPSs promote immunosuppressive
CD8 T-cell responses [57]. While the absence of CD8 T cells6 International Journal of Microbiology
did not inhibit abscess induction [33], their depletion led
to the development of signiﬁcantly larger abscesses [57].
Furthermore, CD8 T cells were localized in the abscess
walls. CD8 T cells that invade sites of inﬂammation have
CD28− phenotypes (Figure 3(b)). These CD8+CD28− cells
are also CD44lowCTLA4+CD39+ and synthesize IL-10 and
TGFβ upon stimulation with ZPSs, which classiﬁes the
cells as immunosuppressive CD8 Treg (CD8 Treg) cells.
CD8+CD28− T-cell populations expand in mice that are
exposed to ZPSs. ZPS-induced CD8+CD28− immunosup-
pressive T cells were shown to inhibit non-speciﬁc CD4
T-cell responses in vitro and ZPS-speciﬁc T-cell responses
in vivo. The adoptive transfer of CD8+ Treg prior to
intraperitoneal challenge with ZPS prevented abscess forma-
tion [57]. Besides the induction of IL-10-producing CD8+
Treg, ZPS also induces immunosuppressive CD4+ Treg,
which produce IL-10 and prevent pathological conditions
such as inﬂammatory bowel disease (IBD) and experimental
autoimmune encephalomyelitis (EAE) [58–60]. Thus, the
immunomodulatory eﬀects of ZPSs are mainly mediated
by the generation of IL-10, an anti-inﬂammatory cytokine.
Besides parasites, viruses and mycobacteria [61], ZPS is the
ﬁrst microbial antigen identiﬁed thus far that can induce
these CD8+ Treg populations.
The induction of CD8 Treg by ZPS occurs independently
of direct T-cell/APC contact, but CD8 T-cell activation is
dependent upon TCR signaling. Stimulation of the cells
with ZPSs induced the activation of proximal TCR signaling
molecules, such as ZAP70, in CD8 Tregs. In contrast to
the proposed oligoclonal CD4 T-cell activation that occurs
through the antigen-speciﬁc TCR, CD8 T-cell activation
is achieved by enhancing TCR crosslinking. Thus, ZPS-
mediated activation of CD4 and CD8 TCRs occur through
signiﬁcantly diﬀerent pathways. In the case of CD4 T cells,
ZPS processing and presentation on MHCII is a prerequisite
for activation. On the other hand, a subpopulation of CD8
T cells is suﬃciently activated by simply crosslinking the
T C R s .I tw i l lb ei n t e r e s t i n gt oe x p l o r ew h yt h eT C R so fC D 4
and CD8 T cells display strikingly diﬀerent ZPS recognition
mechanisms. A recent report by Tsai et al. shows that TLR-
2 agonists induce the diﬀerentiation of CD8 Tregs [62].
Therefore, it is interesting to know that if induction of CD8
Tregs by ZPS also require TLR-2 activation on CD8 T cells.
Also, as the CD8+ Treg are generated by TCR crosslinking,
it is important to know if diﬀerent molecular sizes of ZPS
inﬂuence their expansion. Furthermore, future studies are
needed to determine why ZPSs speciﬁcally activated CD28−
CD8 T-cell populations when the ZPS stimulation of CD4 T
cells was CD28-B7-dependent [41].
6.ZPSModulatesCytokinesof
theImmune System
Intra-abdominal abscess formation is the most important
complication that is associated with abdominal surgeries.
The ZPS-producing B. fragilis bacterium is widely docu-
mented in the formation of intra-abdominal abscesses [63,
64]. At the same time, ZPSs have been shown to cause
unusual immunomodulatory eﬀects in T-cell-mediated
immune protection, which prevented the induction of ab-
scesses. Besides the activation of APCs and CD4T cells, ZPS-
mediated immunomodulation also regulates the production
of cytokines and cell adhesion molecules (Figure 3(a)). ZPSs
induced the production of TNFα and IL-1a on peritoneal
cells, which was shown to be important in the induction
of abscesses [65, 66]. TNFα and IL-1a are required for
the transendothelial migration of neutrophils. Inhibiting the
productionofTNFαresulted in the reductionofintercellular
adhesion molecule 1 (ICAM-1)on polymorphonuclearcells,
which are key players in the formation of intra-abdominal
abscesses. The reduction in ICAM-1 inhibited the migration
of polymorphonuclear cells to the peritoneal cavity and
preventedthedevelopmentofabscesses [66].Besidescausing
the secretion of chemoattractants, such as IL-1, TNFα
and IL-8 [65], which mediate cellular aggregation to the
sites of inﬂammation, ZPS also induces IL-6, a pleiotropic
inﬂammatory cytokine [52]. IL-6 is a cytokine with both
proinﬂammatory andanti-inﬂammatory functionsandplays
important role in T cell stimulation, proliferation and
survival by preventing apoptosis [67–70]. In the absence
of IL-6, the abscess formation is inhibited, which suggests
that the recruitment, activation, and survival of CD4 T cells
are required for the induction of abscess formations. We
and others have recently demonstrated that ZPS induces
the diﬀerentiation of Th17 T cells, which secrete the
proinﬂammatory cytokineIL-17[33,45].Thediﬀerentiation
of CD4 T cells into the Th17 lineages requires TGF-β and
IL-6 (reviewed in [71]). Blocking the production of IL-
17 inhibited the induction of abscess formations by ZPSs,
suggesting that IL-17 plays critical role in the pathogenesis
of ZPS-mediated intra-abdominal abscess formations. While
IL-6stimulationinthepresenceofTGF-βpromotestheTh17
T cell development [71], IL-6 trans-stimulation of T cells
abrogates the development of Foxp-3+ Treg from a naive
CD4+CD25− population [72]. Therefore, it is important to
know whether besides inducing a proinﬂammatory immune
response, IL-6 also suppresses Treg diﬀerentiation during
intra-abdominal challenge with ZPS.
ZPS possesses an unusual biological property that allows
it to prevent the induction of intra-abdominal abscesses
when it is used in subcutaneous vaccinations. Initial studies
have shown that protection from abscess formation was
mediated by IL-2 because abscesses were prevalent in mice
treated with anti-IL-2 antibodies and ZPS. Furthermore, the
adoptive transfer of CD4 T cells from mice that were vacci-
nated with ZPS prevented the induction of intra-abdominal
abscesses in the recipients in an IL-2-dependent manner
[73]. Thus, IL-2 is required for the diﬀerentiation of ZPS-
speciﬁcCD4Tcellstoeﬀectorcells.IL-10isanothercytokine
that is implicated in the protection of ZPS-mediated abscess
induction [56, 57]. IL-10 is a very potent anti-inﬂammatory
cytokine that limits the inﬂammatory responses in exper-
imentally infected models [74–76]. In a rodent model for
ﬁbrosis, a subpopulation of CD4 T cells were shown to
produce the IL-10 upon ZPS immunization [56]. Another
study showed that IL-10-producing CD4 T cells, which are
CD45RBlow, prevented intestinal inﬂammation caused byInternational Journal of Microbiology 7
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Figure 3: ZPSs modulate CD4 and CD8 T-cell responses. (a) Professional antigen presenting cells such as DCs internalize, process, and
present ZPSs on MHCII molecules. The ZPS-MHCII complex is then recognized by TCRs of CD4 T cells in the presence of costimulatory
molecules. This results in the activation and diﬀerentiation of CD4 T cells. ZPS-activated CD4 T cells produce diﬀerent cytokines and have
diverse immune function such as (1) inducing intraabdominal abscess, (2) helping to balance Th1/Th2 immune responses, (3) inducing
the diﬀerentiation of proinﬂammatoryIL-17 T cells, (4) inducing IL-10 producing anti-inﬂammatoryCD4 T regs, and (5) diﬀerentiate into
memoryphenotype. (b) In contrast to theCD4 T-cell activation which requires recognition of ZPS-MHCII complex by TCR, ZPS activation
of CD8 T cells do not require antigen processing and presentation. ZPS crosslinking of the TCRs activate CD8 T cells. ZPS-activated CD8
T cells diﬀerentiate into CD8+CD28− Treg and have diﬀerent immune modulatory eﬀects such as inhibition of abscess induction and CD4
T-cell activation.
Helicobacter hepaticus [58]. We recently showed that upon
ZPS immunization, CD8+ Treg populations expanded, pro-
duced IL-10, and suppressed the CD4-mediated induction
of intra-abdominal abscesses [57]. Besides having speciﬁc
eﬀects on the formation of ZPS-induced abscesses, the IL-
10-producing CD4 Treg populations seemed to broadly
protect the mucosal immune system from diseases medi-
ated by microbial pathogens, such as H. hepaticus-induced
experimental colitis [58, 59]. Therefore, ZPS immunizations
could be attractive tools to prevent infections and T cell
hyperactivation. Based on this theory, it will be interesting
to determine if subcutaneous ZPS vaccinations prevent
diﬀerentiation of the Th1 and Th17 proinﬂammatory CD4
T cell populations.
While the unique immunomodulatory eﬀects of ZPS to
i n d u c ea sw e l la sp r o t e c tt h ef o r mation of intra-abdominal
abscesses has now been known for decades, the underlying
cellular and molecular mechanisms are not yet fully under-
stood. As discussed above, intra-abdominal ZPS challenge
induces the diﬀerentiation of proinﬂammatory CD4 T
cells resulting in abscess formation. However, the same
immunogen, when subcutaneously administered without
an adjuvant, induces the activation of immunosuppressive
CD4 and CD8 Tregs, both secrete immunosuppressive IL-10
molecules and prevent intra-abdominal abscess formation.
However, it is interesting to note that both the CD4 and CD8
Tcellsarerecruitedtotheabscesswalluponintra-abdominal
ZPS administration [45, 57], but the induction of immuno-
suppressive CD4 and CD8 phenotypes were inhibited in
the peritoneum during the abscess development. This raises
important questions pertaining to the possibility of diﬀerent
APC subsets involved in ZPS presentation in the peritoneal
cavity and lymph nodes to induce diﬀerential activation of T
cell subsets. Upon encounter with exogenously administered
ZPS together with SCC adjuvant, ZPS-speciﬁc T cell clones
that may exist in the immune system (not yet characterized)
expand and mediate the intra-abdominal abscess formation.
On the other hand, upon subcutaneous administration
without adjuvant, ZPS activates the APCs diﬀerentially than
during intra-abdominal challenge, or activate a diﬀerent8 International Journal of Microbiology
subset of APCs than those involved in ZPS presentation in
the peritoneal cavity, resulting in the activation of regulatory
T cells. We and others previously reported that ZPS can
induce the upregulation of CD86 on APCs [28, 41] in vitro
and signaling through CD86 is reported in promoting the
generation of IL-10-producing T cells [77, 78]. Thus, it
will be interesting to know if the diﬀerences that occur
in the immune responses when ZPS is administered by
intraperitoneal or subcutaneousroutesare due to diﬀerences
in the presentation of ZPS antigens by the APCs at these
sites. Also, it would be worthwhile to study if subcutaneous
administration of ZPS together with a proinﬂammatory
adjuvant can elicit a protective, anti-inﬂammatory immune
response, or ameliorate abscess induction upon subsequent
intra-abdominal challenge.
7.ZPSBalances the HostImmune System
While the subcutaneous vaccination and intra-abdominal
abscess induction studies identiﬁed interesting immun-
omodulatory aspects of ZPSs, it is important to note that
ZPSs are continuously presented to the immune system.
ZPSs are components of the commensal bacterial ﬂora,
such as B. fragilis in the gut, S. aureus in the skin and
mucosa and S. pneumoniae in the upper respiratory tract.
Accordingly, ZPSs where shown to inﬂuence the Th1/Th2
balance of the host immune system. Colonization with B.
fragilis that contains ZPSs induces a shift of the immune
system towards Th1 responses in germ-free mice, which have
immune systems that are polarized towards Th2 [28]. B.
fragilis that produce the mutated form of ZPS (B. fragilis
￿PSA), which lacks the zwitterionic charges, failed to induce
the Th1 shift of the immune system in germ-free mice. This
modulation of the host immune system by ZPS is mediated
by IL-12, which is produced by DCs and activates signal
transducerandactivator oftranscription 4(STAT4)signaling
molecules in CD4 T cells to produce Th1 cytokines, such
as IFNγ [ 2 8 ] .F u r t h e r m o r e ,Z P Sa d m i n i s t r a t i o ng e n e r a t e s
CD4 memory T cells with proinﬂammatory Th1 and Th17
phenotypes [45]. Thus, ZPS presentation by APCs promotes
the diﬀerentiation of proinﬂammatory CD4 T cells in a Th2-
biased adaptive immune system.
8.ClinicalImplications
TheﬁrstmurinemodelthatwasusedforZPSstudiesassessed
the impact of ZPSs on the formation of intra-abdominal
abscesses. Abdominal abscess formation is a major com-
plication associated with abdominal surgeries, endoscopic
therapiesandinﬂammatory pathologiesthatinvolvemucosal
barrier deﬁciencies, such as inﬂammatory bowel disease
(ulcerative colitis and Crohn’s disease) or diverticulitis. B.
fragilis is one of the most frequently isolated bacteria from
abdominal abscesses [64, 79]. Besides the abscesses develop-
ment,anothercomplicationthatisfrequentlyassociatedwith
abdominal surgeries is adhesion formation. Subcutaneous
immunizations with ZPS have been shown to prevent
or reduce the formations of abscesses and adhesions in
experimental rodent models [26, 56]. These studies also
revealed the role of IL-10-producing regulatory CD4 T cells
and soluble IL-10 and IL-2 in preventing the formation
of intra-abdominal abscesses. Therefore, ZPS injections
during abdominal surgeries are very attractive approaches
to potentially prevent complications and reduce morbidities,
mortalities, and high costs.
In EAE, the murine model for human multiple sclerosis
(MS), pathogenesis is mediated by self-reactive T cells that
target the myelin basic proteinsofthe central nervoussystem
[80]. IL-10 has been reported to be a regulatory cytokine in
EAE. Elevated levels of IL-10 were associated with disease
remission in EAE [81]a n dM S[ 82]. Moreover, while IL-
10 deﬁcient mice developed severe EAE [83, 84], transgenic
mice that overexpressed human IL-10 were resistant to the
disease [85]. Importantly, a recent report by Ochoa-Rep´ araz
et al. shows that ZPS can protect the mice from EAE through
production of IL-10 producing CD4 Tregs [60]. Thus,
ZPS immunizations, which induce IL-10 production by
subpopulations of CD4+ and regulatory CD8+ T cells, may
have the therapeuticpotential to inﬂuence the progression of
MS.
Crohn’s disease is believed to be caused by T cell immu-
nity abnormalities (e.g., pathologic T cell balances in the
mucosal-associated immune system) [86]. ZPSs have been
shown tocorrecttheT cellimbalance ingerm-free mice [28],
and recent studies demonstrated that immunizations with
ZPSs from B. fragilis prevented inﬂammatory bowel diseases
(IBD) in mice [58, 59]. These ZPS studies enhance our
understanding of the underlying immunologic conditions
and the interactions between themicrobial ﬂora and the host
immune system that promote IBD.
Another widely discussed clinical implication of ZPS
usage is in the prevention of allergies ([28] and reviewed in
[87]). Brieﬂy, in industrialized nations, improved sanitation
conditions and the excessive use of antibiotics and vaccines
eliminated many of thecommensal andpathogenicﬂora that
were present in our bodies. These communities of microor-
ganisms play critical roles in shaping our immune systems.
As a consequence of their elimination, certain populations
of people within developed nations are more susceptible
to immune system disorders, such as allergies and asthma,
which are characterized by Th2 immune responses. Because
ZPSs were shown to ameliorate the defective Th2-biased
immune systems in germ-free mice, ZPS immunizations
might also prevent allergies and asthma.
A recent study reported that vaccines with synthetic ZPS
motifs provided protection against group B streptococcus
infections [36].This implies that ZPSsare vaccinecandidates
not only against bacterial strains carrying the speciﬁc
polysaccharide but also to related capsulated bacterial
species. Sp1-producing S. pneumoniae is still the most
frequentcauseofbacterialpneumonia,which isoftenalethal
disease. So far, more than 90 serotypes of S. pneumonia have
been identiﬁed. Two vaccines currently in use to prevent
pneumococcal infections are a protein-polysaccharide
pneumococcal conjugate vaccine (Prevenar13), and a 23-
valent pneumococcal polysaccharide vaccine (PPSV, also
known as Pneumovax23) (refer the Center for DiseaseInternational Journal of Microbiology 9
Control web site, http://www.cdc.gov/ncidod/aip/research/
spn.html). Pneumococcal polysaccharide vaccines are highly
eﬀective in adults, though not in children, suggesting that
withoutconjugatedproteins,carbohydratesalonecaninduce
a protective immune response in adults. Interestingly, both
thepneumococcalvaccinesalsocontainthecapsularpolysac-
charide from S.pneumoniae serotype 1,thestrain which pro-
ducetheZPSSp1(Prevenar13web page,http://www.prevnar
.com/What-Is-Prevnar13, and Pneumovax23 web page, http:
//www.merck.com/product/usa/pi circulars/p/pneumovax
23/pneumovax pi.pdf).
As the ZPS Sp1 is able to activate CD4 T cells of adaptive
immune system, future studies can optimize ZPS concen-
trations in vaccines to prevent pneumococcal and related
bacterial infections.
Thus, the unusual immunomodulatory properties of
ZPSs make them attractive candidates for the treatment of
many disease conditions. However, ZPS-based vaccination
strategies are still in early experimental stages. To opti-
mize ZPSs as immunoregulatory/vaccine candidates, more
research aimed at elucidating the mechanisms of immune
modulation by ZPSs is needed.
9.Summary
Unlikenegatively charged polysaccharides, bacterial polysac-
charides with both positively and negatively charged sugar
molecules are able to activate CD4 and CD8 T cells of the
adaptive immune system. This phenomenon demonstrates
thatmoleculesotherthan proteinaceous antigens are capable
of activation of conventional αβT cells. However, the thymic
selection mechanisms underlying the in vivo generation
of this ZPS-speciﬁc T cell clones are currently unknown.
Development of speciﬁc TCR transgenic mouse models are
required to understand the selection and development of
ZPS-speciﬁc T cells. These cells may be more enriched in
the mucosae as ZPS-producing bacteria such as B. fragilis
and S. pneumoniae are contained within the commensal
ﬂora of the gut and upper respiratory track, respectively.
Thus, these ZPS-speciﬁc T cells are in constant contact with
ZPS presented by APCs of the mucosal immune system.
Accordingly, the steady-state presentation of this unique
immunomodulatory microbial antigen is beneﬁcial to our
immune system as it can play pivotal role in shaping a
functionally competent, immune system. However, when
ZPSs are accidently introduced into a sterile area, such
as the peritoneal cavity during intra-abdominal surgical
procedures when abdominal contents can spill into the
peritoneal cavity, or by intraperitoneal inoculation with ZPS
and a sterile cecal adjutant, a rapid recruitment of ZPS-
speciﬁc, proinﬂammatory CD4 T cells may be induced.
This recruitment of CD4 T cells together with other innate
cells results in the generation of intra-abdominal abscess,
a defensive mechanism of the body to contain the infec-
tion. Recent studies have shown that ZPS-mediated intra-
abdominalabscessinductiondependsonZPSprocessingand
presentation on MHCII molecules by APCs for recognition
and activation of CD4 T cells. However, future studies are
needed to determine how ZPS molecules are bound to
MHCII, a paradigm described so far only for protein anti-
gens. Diﬃculties in crystallizing sugar molecules hamper the
study of the structural aspects of ZPS-MHCII interactions
as well as those of the TCR-ZPS-MHCII-complex. However,
newer approaches such as molecular docking [88]m a yb e
useful in resolving the technical diﬃculties in analyzing ZPS-
MHCII interactions.
The unique immunomodulatory property of ZPS is
its ability to prevent the intra-abdominal abscess develop-
ment when the experimental models are subcutaneously
immunized with ZPS prior to intraperitoneal inocula-
tion. During subcutaneous inoculation, ZPSs induce anti-
inﬂammatory, immunosuppressive T cells. This population
includes both the regulatory CD4 and CD8 T cells, which
secrete the immunosuppressive cytokine IL-10. Thus, the
same immunogen can elicit both proinﬂammatory and
anti-inﬂammatory responses dependent upon the route
and mode of administration. While the induction of
proinﬂammatory responses and abscess induction requires
ZPS inoculation with sterile cecal content as an adjuvant,
induction of immunosuppressive responses by ZPS does not
require an adjuvant. Thus, besides the possible diﬀerences
i na n t i g e np r e s e n t a t i o nb yA P C si ne l i c i t i n gt h e s eo p p o s i n g
biological responses, the role mediated by adjuvant also
needs to be studied in more detail. Moreover, further
studies are required to understand the mechanisms of APC-
independent activation of CD8 T regs upon subcutaneous
ZPS immunization.
Regardless of the unanswered questions, the accumu-
lating data on ZPS is changing our understanding about
carbohydrate immunology. We now know that endosome
acidiﬁcation by ZPS can enhance APC functions, such as
the processing and presentation of antigens. This is in
disagreement with the traditional view that carbohydrates
accumulate in the lysosomes and inhibit antigen process-
ing and presentation. ZPS studies have also shown that
besides proteins, carbohydrates can also bind to MHCII, an
observation that opens the door for further studies in the
area of antigen processing and presentation. Moreover, this
paves the way for the design of new carbohydrate vaccines
against infectious organisms. Additionally, ZPS studies have
revealed that some carbohydrates antigens can activate both
the CD4and CD8 Tcellsofthe adaptive immune systemand
induce proinﬂammatory or immunosuppressive responses
upon administration through diﬀerent routes. The ability
to induce the production of anti-inﬂammatory cytokines,
s u c ha sI L - 1 0 ,m a k e sZ P S sa na t t r a c t i v em o l e c u l ef o rt h e
generation of vaccines that can potentially prevent bacterial
infections, inﬂammatory bowel diseases, and autoimmune
diseases, such as multiple sclerosis.
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